1. Oncometabolite d-2HG alters T cell metabolism to impair CD8 + T cell function.
- Author
-
Notarangelo G, Spinelli JB, Perez EM, Baker GJ, Kurmi K, Elia I, Stopka SA, Baquer G, Lin JR, Golby AJ, Joshi S, Baron HF, Drijvers JM, Georgiev P, Ringel AE, Zaganjor E, McBrayer SK, Sorger PK, Sharpe AH, Wucherpfennig KW, Santagata S, Agar NYR, Suvà ML, and Haigis MC
- Subjects
- Animals, Gain of Function Mutation, Humans, Interferon-gamma metabolism, L-Lactate Dehydrogenase antagonists & inhibitors, L-Lactate Dehydrogenase metabolism, Mice, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, Carcinogenesis genetics, Carcinogenesis metabolism, Glutarates metabolism, Isocitrate Dehydrogenase genetics, Isocitrate Dehydrogenase metabolism, Neoplasms genetics, Neoplasms immunology, Neoplasms metabolism
- Abstract
Gain-of-function mutations in isocitrate dehydrogenase (IDH) in human cancers result in the production of d-2-hydroxyglutarate (d-2HG), an oncometabolite that promotes tumorigenesis through epigenetic alterations. The cancer cell-intrinsic effects of d-2HG are well understood, but its tumor cell-nonautonomous roles remain poorly explored. We compared the oncometabolite d-2HG with its enantiomer, l-2HG, and found that tumor-derived d-2HG was taken up by CD8
+ T cells and altered their metabolism and antitumor functions in an acute and reversible fashion. We identified the glycolytic enzyme lactate dehydrogenase (LDH) as a molecular target of d-2HG. d-2HG and inhibition of LDH drive a metabolic program and immune CD8+ T cell signature marked by decreased cytotoxicity and impaired interferon-γ signaling that was recapitulated in clinical samples from human patients with IDH1 mutant gliomas.- Published
- 2022
- Full Text
- View/download PDF